Glaxo to Evaluate Quantum Dot SNP Detection System | GenomeWeb

NEW YORK, Jan 16 - Quantum Dot said Tuesday that GlaxoSmithKline has agreed to help in evaluating the company’s SNP detection assays.

Financial terms of the deal were not disclosed. Andy Watson, vice president of systems at QDC, said the evaluation could potentially lead to a licensing agreement.

"They’ll be using their expertise to evaluate the data we generate and to see how applicable it is to their needs," said Watson.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.